Last reviewed · How we verify
NCT03233867
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
trial in Attention Deficit Hyperactivity Disorder in 2,503 participants. Completed in 3 August 2018.
3 August 2018
Quick facts
| Lead sponsor | Aevi Genomic Medicine, LLC, a Cerecor company |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,503 |
| Start date | 14 August 2017 |
| Primary completion | 3 August 2018 |
| Estimated completion | 3 August 2018 |
| Sites | 1 location across United States |
Conditions studied
- Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →
Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company — full company profile →
Who can join
Adults 6 to 17, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) to assess CNVs in specific genes involved in glutamatergic signaling and neuronal connectivity. The screening in this study will be conducted through a combination of online and site performed activities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03233867
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention Deficit Hyperactivity Disorder
Currently open trials in the same condition.
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
- NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
- NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
- NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting
Other Aevi Genomic Medicine, LLC, a Cerecor company trials
Trials by the same sponsor.
- NCT04412057 — Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury · Phase 2 · completed
- NCT03609619 — PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations · Phase 2 · completed
- NCT03265119 — PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations · Phase 2 · completed
- NCT03006367 — Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD · Phase 1 · completed
- NCT02895906 — Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03233867 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aevi Genomic Medicine, LLC, a Cerecor company
- Last refreshed: 6 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03233867.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing